Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00268528 · ClinicalTrials.gov registry record
Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission
A clinical trial of Childhood Acute Lymphoblastic Leukemia in Remission, sponsored by Children's Oncology Group.
- Completed
- Registry status
- 720
- Enrollment target
- 20
- Study locations
NCT00268528 is a study of Childhood Acute Lymphoblastic Leukemia in Remission that has completed, run by Children's Oncology Group. The registered enrollment target is 720 participants, above the 136-participant average among 9 other Childhood Acute Lymphoblastic Leukemia in Remission trials with a reported enrollment target (429% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00268528, a study of Childhood Acute Lymphoblastic Leukemia in Remission, has completed, sponsored by Children's Oncology Group.
- COMPLETED
- Registry status
- 720 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial is assessing compliance with long-term mercaptopurine treatment in young patients with acute lymphoblastic leukemia in remission. Assessing why young patients who have acute lymphoblastic leukemia may not take their medications as prescribed may help identify ways to assist them in taking their medications more consistently and may improve long-term treatment outcomes.
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- OTHER Questionnaire Administration
- DRUG Methotrexate
- DRUG Mercaptopurine
- BEHAVIORAL Compliance Monitoring
Study Locations (20)
California
- Kaiser Permanente Downey Medical Center - Downey
- City of Hope Comprehensive Cancer Center - Duarte
- Loma Linda University Medical Center - Loma Linda
- Miller Children's and Women's Hospital Long Beach - Long Beach
- Children's Hospital Los Angeles - Los Angeles
- Mattel Children's Hospital UCLA - Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
- Valley Children's Hospital - Madera
- Children's Hospital and Research Center at Oakland - Oakland
- Lucile Packard Children's Hospital Stanford University - Palo Alto
- University of California Davis Comprehensive Cancer Center - Sacramento
- Rady Children's Hospital - San Diego - San Diego
- UCSF Medical Center-Parnassus - San Francisco
- Harbor-University of California at Los Angeles Medical Center - Torrance
Alabama
- Children's Hospital of Alabama - Birmingham
- University of Alabama at Birmingham Cancer Center - Birmingham
Connecticut
- University of Connecticut - Farmington
- Connecticut Children's Medical Center - Hartford
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Colorado
- Children's Hospital Colorado - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 720 participants |
| Start Date | 2005-05-30 |
| Est. Completion | 2020-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00268528
The ClinicalTrials.gov registry entry for NCT00268528 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 720 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 136-participant average among 9 other Childhood Acute Lymphoblastic Leukemia in Remission trials with a reported enrollment target (429% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Childhood Acute Lymphoblastic Leukemia in Remission appearing as the primary indexed condition, and to 5 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00268528 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Connecticut.
Frequently Asked Questions
What is clinical trial NCT00268528 about?
NCT00268528 is a clinical study titled "Study to Assess Compliance With Long-Term Mercaptopurine Treatment in Young Patients With Acute Lymphoblastic Leukemia in Remission". This clinical trial is assessing compliance with long-term mercaptopurine treatment in young patients with acute lymphoblastic leukemia in remission. Assessing why young patients who have acute lymphoblastic leukemia may not take their medications as prescribed may help identify ways to assist them ...
What is the current status of trial NCT00268528?
This trial is currently completed. The enrollment target is 720 participants. The study started on 2005-05-30. Estimated completion is 2020-06-30.
What conditions does trial NCT00268528 study?
This clinical trial studies the following conditions: Childhood Acute Lymphoblastic Leukemia in Remission.
What interventions are being tested in trial NCT00268528?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Questionnaire Administration (OTHER), Methotrexate (DRUG), Mercaptopurine (DRUG), Compliance Monitoring (BEHAVIORAL).
Who is sponsoring clinical trial NCT00268528?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00268528 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Childhood Acute Lymphoblastic Leukemia in Remission
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Culturally Adapted Parenting Intervention for Spanish-Speaking Parents in Improving Outcomes of Younger Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia Survivors at Risk for Late Neurocognitive Effects
COMPLETED · NA
-
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
COMPLETED · Phase 2
-
DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia
COMPLETED
-
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
COMPLETED · Phase 2
-
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
COMPLETED · Phase 3
-
ALL-Active: A Family-Based Lifestyle Program for Pediatric Acute Leukemia Patients
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.